ID   VGFR1_HUMAN             Reviewed;        1338 AA.
AC   P17948; A8KA71; O60722; P16057; Q12954;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   02-NOV-2010, entry version 138.
DE   RecName: Full=Vascular endothelial growth factor receptor 1;
DE            Short=VEGFR-1;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 1;
DE            Short=FLT-1;
DE   AltName: Full=Tyrosine-protein kinase FRT;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT;
DE   AltName: Full=Vascular permeability factor receptor;
DE   Flags: Precursor;
GN   Name=FLT1; Synonyms=FLT, FRT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FLT1).
RC   TISSUE=Placenta;
RX   MEDLINE=90221591; PubMed=2158038;
RA   Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H.,
RA   Sato M.;
RT   "Nucleotide sequence and expression of a novel human receptor-type
RT   tyrosine kinase gene (flt) closely related to the fms family.";
RL   Oncogene 5:519-524(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM FLT1).
RC   TISSUE=Umbilical vein;
RA   Yu Y., Whitney R.G., Sato J.D.;
RT   "Coding region for human VEGF receptor FLT1 (VEGFR-1).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SFLT1), AND PROTEIN SEQUENCE OF
RP   N-TERMINUS.
RC   TISSUE=Umbilical vein;
RX   MEDLINE=94068470; PubMed=8248162; DOI=10.1073/pnas.90.22.10705;
RA   Kendall R.L., Thomas K.A.;
RT   "Inhibition of vascular endothelial cell growth factor activity by an
RT   endogenously encoded soluble receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SFLT1).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SFLT1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1018-1058 (ISOFORM FLT1).
RX   MEDLINE=87307638; PubMed=3040650;
RA   Matsushime H., Yoshida M.C., Sasaki M., Shibuya M.;
RT   "A possible new member of tyrosine kinase family, human frt sequence,
RT   is highly conserved in vertebrates and located on human chromosome
RT   13.";
RL   Jpn. J. Cancer Res. 78:655-661(1987).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, PHOSPHORYLATION AT TYR-1213; TYR-1242;
RP   TYR-1327 AND TYR-1333, AND MUTAGENESIS OF TYR-914; TYR-1213; TYR-1242;
RP   TYR-1327 AND TYR-1333.
RX   MEDLINE=98389777; PubMed=9722576; DOI=10.1074/jbc.273.36.23410;
RA   Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.;
RT   "Identification of vascular endothelial growth factor receptor-1
RT   tyrosine phosphorylation sites and binding of SH2 domain-containing
RT   molecules.";
RL   J. Biol. Chem. 273:23410-23418(1998).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1048 AND TYR-1053, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [10]
RP   STRUCTURE BY NMR OF 129-229.
RX   MEDLINE=20013066; PubMed=10543948; DOI=10.1006/jmbi.1999.3134;
RA   Starovasnik M.A., Christinger H.W., Wiesmann C., Champe M.A.,
RA   de Vos A.M., Skelton N.J.;
RT   "Solution structure of the VEGF-binding domain of Flt-1: comparison of
RT   its free and bound states.";
RL   J. Mol. Biol. 293:531-544(1999).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-60; LYS-144; GLN-281; ILE-422;
RP   GLN-781; VAL-938; ALA-982 AND VAL-1061.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for VEGF, VEGFB and PGF. Has a tyrosine-protein
CC       kinase activity. The VEGF-kinase ligand/receptor signaling system
CC       plays a key role in vascular development and regulation of
CC       vascular permeability. Isoform SFlt1 may have an inhibitory role
CC       in angiogenesis.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts in vitro with various phosphotyrosine-binding
CC       proteins, including PLC-gammas, PTPN11, GRB2, CRK and NCK1.
CC   -!- SUBCELLULAR LOCATION: Isoform Flt1: Cell membrane; Single-pass
CC       type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform sFlt1: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist;
CC       Name=Flt1;
CC         IsoId=P17948-1; Sequence=Displayed;
CC       Name=sFlt1;
CC         IsoId=P17948-2; Sequence=VSP_002955, VSP_002956;
CC   -!- TISSUE SPECIFICITY: Mostly in normal lung, but also in placenta,
CC       liver, kidney, heart and brain tissues. Specifically expressed in
CC       most of the vascular endothelial cells, and also expressed in
CC       peripheral blood monocytes. It is not expressed in tumor cell
CC       lines. Isoform sFlt1 is strongly expressed in placenta.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X51602; CAA35946.1; -; mRNA.
DR   EMBL; AF063657; AAC16449.2; -; mRNA.
DR   EMBL; U01134; AAC50060.1; -; mRNA.
DR   EMBL; AK292936; BAF85625.1; -; mRNA.
DR   EMBL; CH471075; EAX08431.1; -; Genomic_DNA.
DR   EMBL; BC039007; AAH39007.1; -; mRNA.
DR   EMBL; D00133; BAA00080.1; -; Genomic_DNA.
DR   IPI; IPI00018335; -.
DR   IPI; IPI00216043; -.
DR   PIR; A49636; A49636.
DR   PIR; S09982; S09982.
DR   RefSeq; NP_001153392.1; -.
DR   RefSeq; NP_002010.2; -.
DR   UniGene; Hs.594454; -.
DR   PDB; 1FLT; X-ray; 1.70 A; X/Y=132-226.
DR   PDB; 1QSV; NMR; -; A=129-229.
DR   PDB; 1QSZ; NMR; -; A=129-229.
DR   PDB; 1QTY; X-ray; 2.70 A; T/U/X/Y=129-229.
DR   PDB; 1RV6; X-ray; 2.45 A; X/Y=130-229.
DR   PDB; 2XAC; X-ray; 2.71 A; C/X=129-226.
DR   PDB; 3HNG; X-ray; 2.70 A; A=801-1158.
DR   PDBsum; 1FLT; -.
DR   PDBsum; 1QSV; -.
DR   PDBsum; 1QSZ; -.
DR   PDBsum; 1QTY; -.
DR   PDBsum; 1RV6; -.
DR   PDBsum; 2XAC; -.
DR   PDBsum; 3HNG; -.
DR   ProteinModelPortal; P17948; -.
DR   SMR; P17948; 32-550, 753-1048, 809-1165.
DR   DIP; DIP-643N; -.
DR   MINT; MINT-127610; -.
DR   STRING; P17948; -.
DR   PhosphoSite; P17948; -.
DR   PRIDE; P17948; -.
DR   Ensembl; ENST00000282397; ENSP00000282397; ENSG00000102755.
DR   GeneID; 2321; -.
DR   KEGG; hsa:2321; -.
DR   UCSC; uc001usb.2; human.
DR   UCSC; uc001usc.2; human.
DR   CTD; 2321; -.
DR   GeneCards; GC13M028874; -.
DR   HGNC; HGNC:3763; FLT1.
DR   HPA; HPA011740; -.
DR   HPA; HPA014290; -.
DR   MIM; 165070; gene.
DR   PharmGKB; PA28180; -.
DR   HOGENOM; HBG402887; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P17948; -.
DR   OMA; KPQIYEK; -.
DR   OrthoDB; EOG9VDSHT; -.
DR   PhylomeDB; P17948; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; vegfr1_pathway; VEGFR1 specific signals.
DR   Reactome; REACT_12529; Signaling by VEGF.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 9421; -.
DR   ArrayExpress; P17948; -.
DR   Bgee; P17948; -.
DR   CleanEx; HS_FLT1; -.
DR   Genevestigator; P17948; -.
DR   GermOnline; ENSG00000102755; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor...; IDA:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007565; P:female pregnancy; TAS:ProtInc.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IEA:InterPro.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial...; IDA:BHF-UCL.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020722; Tyr_kinase_VEGF1_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   InterPro; IPR009135; Tyr_prot_kinase_VEGFR1_rcpt_N.
DR   InterPro; IPR009134; Tyr_prot_kinase_VEGFR_rcpt_N.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 8.
DR   PANTHER; PTHR23256:SF225; Tyr_kinase_VEGF1_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 4.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01832; VEGFRECEPTOR.
DR   PRINTS; PR01833; VEGFRECEPTR1.
DR   SMART; SM00409; IG; 5.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Complete proteome; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     26
FT   CHAIN        27   1338       Vascular endothelial growth factor
FT                                receptor 1.
FT                                /FTId=PRO_0000016768.
FT   TOPO_DOM     27    758       Extracellular (Potential).
FT   TRANSMEM    759    780       Helical; (Potential).
FT   TOPO_DOM    781   1338       Cytoplasmic (Potential).
FT   DOMAIN       32    123       Ig-like C2-type 1.
FT   DOMAIN      151    214       Ig-like C2-type 2.
FT   DOMAIN      230    327       Ig-like C2-type 3.
FT   DOMAIN      335    421       Ig-like C2-type 4.
FT   DOMAIN      428    553       Ig-like C2-type 5.
FT   DOMAIN      556    654       Ig-like C2-type 6.
FT   DOMAIN      661    747       Ig-like C2-type 7.
FT   DOMAIN      827   1158       Protein kinase.
FT   NP_BIND     833    841       ATP (By similarity).
FT   ACT_SITE   1022   1022       Proton acceptor (By similarity).
FT   BINDING     861    861       ATP (By similarity).
FT   MOD_RES    1048   1048       Phosphotyrosine.
FT   MOD_RES    1053   1053       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1169   1169       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1213   1213       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1242   1242       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1327   1327       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1333   1333       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD    100    100       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    164    164       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    196    196       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    251    251       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    323    323       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    402    402       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    474    474       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    547    547       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    597    597       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    620    620       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    625    625       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    666    666       N-linked (GlcNAc...) (Potential).
FT   DISULFID     53    107       Potential.
FT   DISULFID    158    207
FT   DISULFID    252    311       Potential.
FT   DISULFID    454    535       Potential.
FT   DISULFID    577    636       Potential.
FT   DISULFID    682    731       Potential.
FT   VAR_SEQ     657    687       DQEAPYLLRNLSDHTVAISSSTTLDCHANGV -> GEHCNK
FT                                KAVFSRISKFKSTRNDCTTQSNVKH (in isoform
FT                                sFlt1).
FT                                /FTId=VSP_002955.
FT   VAR_SEQ     688   1338       Missing (in isoform sFlt1).
FT                                /FTId=VSP_002956.
FT   VARIANT      60     60       K -> T (in dbSNP:rs56409818).
FT                                /FTId=VAR_042045.
FT   VARIANT     128    128       I -> L (in dbSNP:rs35073261).
FT                                /FTId=VAR_049719.
FT   VARIANT     144    144       E -> K (in dbSNP:rs55974987).
FT                                /FTId=VAR_042046.
FT   VARIANT     281    281       R -> Q (in dbSNP:rs55687105).
FT                                /FTId=VAR_042047.
FT   VARIANT     422    422       L -> I (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042048.
FT   VARIANT     781    781       R -> Q (in a glioma low grade
FT                                oligodendroglioma sample; somatic
FT                                mutation).
FT                                /FTId=VAR_042049.
FT   VARIANT     938    938       M -> V (in dbSNP:rs35549791).
FT                                /FTId=VAR_042050.
FT   VARIANT     982    982       E -> A (in dbSNP:rs35832528).
FT                                /FTId=VAR_042051.
FT   VARIANT    1061   1061       L -> V (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042052.
FT   MUTAGEN     914    914       Y->F: No loss of phosphorylation.
FT   MUTAGEN    1213   1213       Y->F: Loss of phosphorylation.
FT   MUTAGEN    1242   1242       Y->F: Loss of phosphorylation.
FT   MUTAGEN    1327   1327       Y->F: Loss of phosphorylation.
FT   MUTAGEN    1333   1333       Y->F: Loss of phosphorylation.
FT   CONFLICT    490    490       F -> S (in Ref. 2; AAC16449).
FT   CONFLICT    779    779       F -> L (in Ref. 1; CAA35946).
FT   STRAND      135    137
FT   STRAND      144    148
FT   STRAND      154    156
FT   STRAND      168    171
FT   TURN        172    174
FT   STRAND      175    177
FT   STRAND      181    187
FT   TURN        188    190
FT   STRAND      191    196
FT   HELIX       199    201
FT   STRAND      203    211
FT   STRAND      214    224
SQ   SEQUENCE   1338 AA;  150769 MW;  FF3381EEFAF0787C CRC64;
     MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
     WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
     ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
     GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
     KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
     MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
     AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
     TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
     DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
     VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
     HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
     PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
     VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
     RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
     VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
     QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
     TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
     RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
     DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
     PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
     PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
     TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
     CSPPPDYNSV VLYSTPPI
//
